Opinion & analysis

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Is a suffix that distinguishes biosimilars and other biologic products necessary in adverse event reporting? The US FDA says yes, although to date, nearly every adverse event report received by the FDA have identified biosimilars simply by their brand names.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Petition Suggests Environmental Laws Compel FDA To Ban Oxybenzone, Octinoxate In Sunscreens

Infographic – 2018 Pharma Pipeline Snapshot

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

FDA Plans Consumer Survey To Better Understand Cosmetics Allergy Prevalence

OTC Distribution in Europe – The New Global Agenda

Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says

Testing Ranitidine with Too Much Heat Could Generate NDMA, FDA Say

The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

Investigator Horror Stories 3: Boozing On The Job? Yup, That Happened – As Have These Other Shocking Tales Of Irregular FDA Inspections

How To Pay For The New Wave Of Gene Therapies

2021 J.P. Morgan Healthcare Conference Review

Nitrosamine Episode Could Lead To Paradigm Shift In Quality

Drug/Software Combo Platform Coming Soon To US FDA, Gottlieb Says

You Work In The Pharmaceutical Industry; Here’s Why You Should Care About The Novartis Payments